Quest Diagnostics Inc vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B). The key difference: Quest Diagnostics Inc and iShares iBoxx $ Inv Grade Corporate Bond ETF are close in size by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days on average.
| DGX | LQD | |
|---|---|---|
Market Cap | $25.48B | $28.50B |
Volume | 941,866 | 37,320,110 |
Sector | Health | Fixed Income |
52-Week High | $247.45 | $112.91 |
52-Week Low | $173.49 | $101.83 |
Typical Hold Time | 56 Days | 125 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
LQD trades at $102.47 with a slight 0.34% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September 2026 and concerns about rising Treasury yields impacting investment-grade corporate bonds.
The outlook remains cautious as rising interest rates pressure bond ETFs, though LQD's 4.8% yield and high-quality portfolio provide some stability. Key risks include further bond market volatility and economic uncertainty, while institutional activity shows mixed sentiment with elevated short positions.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →